Qiagen N.V. $QGEN Stock: Moors & Cabot Inc. Lowers Stake

Moors & Cabot Inc. lowered its stake in Qiagen N.V. (NYSE:QGEN – Free Report) by 26.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 250,461 shares of the company’s stock after selling 89,000 shares during the quarter. Moors & Cabot Inc.’s holdings in Qiagen were worth $10,960,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Amundi raised its stake in Qiagen by 12.4% during the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after buying an additional 524,959 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Qiagen during the 1st quarter valued at $14,647,000. Troluce Capital Advisors LLC bought a new position in shares of Qiagen during the 1st quarter valued at $14,514,000. Hsbc Holdings PLC purchased a new position in shares of Qiagen in the 1st quarter worth $12,916,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Qiagen by 20.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock worth $66,649,000 after buying an additional 286,665 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

QGEN has been the subject of a number of recent research reports. Barclays downgraded Qiagen from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $55.00 to $53.00 in a research note on Wednesday, October 28th. Citigroup reiterated a “neutral” rating and issued a $52.00 price objective (up from $45.00) on shares of Qiagen in a research note on Monday, October 26th. DZ Bank cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. JPMorgan Chase & Co. downgraded shares of Qiagen from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $55.00 to $52.00 in a report on Thursday, October 22nd. Finally, Jefferies Financial Group restated a “buy” rating and set a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. Four investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $46.34.

Get Our Latest Analysis on Qiagen

Qiagen Stock Up 0.1%

NYSE QGEN opened at $49.92 on Monday. The stock’s 50 day moving average is $46.51 and its 200 day moving average is $42.65. The company has a current ratio of 2.63, a quick ratio of 2.14 and a debt-to-equity ratio of 0.43. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The stock has a market cap of $10.29 billion, a PE ratio of 27.28, a P/E/G ratio of 4.00 and a beta of 0.56.

Qiagen (NYSE:QGEN – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $547.87 million during the quarter, compared to analyst estimates of $538.61 million. Qiagen had a net margin of 18.19% and a return on equity of 14.70%. Qiagen’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period last year, the firm posted $0.61 earnings per share. Research analysts predict that Qiagen N.V. will post 2.44 EPS for the current fiscal year.

Qiagen Company Profile

(Free Report)

QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials. The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.

Read More

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN – Free Report).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.